Jazz Pharmaceuticals price target raised to $179 from $175 at RBC Capital

RBC Capital raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $179 from $175 and keeps an Outperform rating on the shares. The company’s sole pipeline igniter, zanidatamab is on the path to becoming the next driver of the oncology portfolio over the long term with the upcoming PDUFA on January 29 in second-line HER2-positive biliary tract cancer, and the firm sees zani’s potential as a meaningful contributor to Jazz’s top line, the analyst tells investors in a research note.